Autoantibody occurrence in hairy cell leukemia

¹First Department of Medicine Semmelweis University Medical School, Budapest, Hungary.

|September 1, 1993

Summary

Autoantibodies can be present in hairy cell leukemia (HCL) patients before interferon-alpha therapy, even without clinical autoimmune disease symptoms. This finding is crucial for understanding HCL complications.

Area of Science:

Hematology
Immunology
Oncology

Background:

Autoimmune syndromes may be a distinct feature in hairy cell leukemia (HCL) patients.
Interferon-alpha (IFN-alpha) therapy has been implicated in the development of autoantibodies in HCL.
This study investigated autoantibody prevalence in HCL patients before IFN-alpha treatment.

Purpose of the Study:

To determine the occurrence of autoantibodies in HCL patients before initiating interferon-alpha therapy.
To assess the relationship between autoantibodies and clinical autoimmune disease in HCL.
To evaluate autoantibody presence irrespective of disease stage or prior splenectomy.

Main Methods:

Analyzed sera from 24 B-cell HCL patients and 1 T-HCL patient.
Assessed antinuclear antibodies (ANA) via indirect immunofluorescence (IF).
Quantified rheumatoid factors (RF) using ELISA and determined granulocyte-specific ANA and antineutrophil cytoplasmic antibodies (ANCA) by IF.

Main Results:

No overt autoimmune disease syndromes were observed in the HCL patients.
Autoantibodies were detected in a subset of B-HCL patients: rheumatoid factors (6/24), antinuclear antibodies (5/24), and anti-cytoplasmic antibodies (3/24).
The presence of autoantibodies appeared unrelated to clinical disease stage or splenectomy status.

Conclusions:

Autoantibodies can be present in hairy cell leukemia patients prior to interferon-alpha treatment.
Autoantibody occurrence in HCL is possible even without clinically apparent autoimmune disease.
These findings suggest autoantibodies are an intrinsic feature in some HCL cases, independent of therapy.

Related Experiment Videos

Autoantibody occurrence in hairy cell leukemia

Related Concept Videos

Adipokine secretion and lipolysis following gender-affirming treatment in transgender individuals.

Posterolateral corner injuries: Epidemiology, anatomy, biomechanics and diagnosis.

Monocyte activation drives preservation of membrane thiols by promoting release of oxidised membrane moieties via extracellular vesicles.

Detection of Activation Antigens on Chronic Lymphocytic Leukaemia Cells.

Internal fixation of femoral neck stress fractures in young female athletes with a dynamic locking plate.

Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement.

Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia.

Risks and benefits of gene therapy and transplantation in sickle cell disease. Comment on: "HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial"

Separating dose schedule from disease biology in CD19 CAR T-cell therapy. Comment on: "A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma".

Safety, feasibility, and efficacy of anti-PD-1 therapy for the treatment of classical Hodgkin lymphoma.

Defining the therapeutic window of NLRP6 modulation in graft-versus-host disease. Comment on: "NLRP6 regulates donor T cell activation and acute graft-versus-host disease via ZAP-70-Erk pathway".

Belumosudil achieves clinical response in chronic graft-versus-host disease with varying organ-specific response kinetics: an analysis from the phase II ROCKstar trial.

Related Experiment Videos

Autoantibody occurrence in hairy cell leukemia

Area of Science:

Background:

Purpose of the Study:

Main Methods:

Main Results:

Conclusions:

Related Concept Videos

Related Articles